Granules India has officially scheduled an Extraordinary General Meeting (EGM) for January 22, 2026 at 11:30 AM IST through video conferencing to seek shareholder approval for its comprehensive ₹1,762.50 crore fundraising initiative through preferential allotment.

EGM and Voting Details

The pharmaceutical company has announced detailed procedures for the upcoming EGM, with remote e-voting commencing from January 19, 2026 (9:00 AM IST) and concluding on January 21, 2026 (5:00 PM IST). Shareholders holding shares as of the cut-off date of January 15, 2026 will be eligible to participate in the voting process.

Convertible Warrants Issuance

The board has approved the issuance of up to 2.50 crore convertible warrants at ₹585.00 per warrant, targeting both promoter group and non-promoter investor categories. The warrants are convertible into equivalent equity shares within 18 months from allotment date.

Equity Shares Component

The company will also issue 51.28 lakh fully paid-up equity shares exclusively to non-promoter investors at ₹585.00 per share, raising ₹300.00 crores. The equity shares will be distributed among nine institutional investors including 360 ONE Equity Opportunity Fund, Public Sector Pension Investment Board, and other fund houses.

Investor Allocation and Fund Utilization

The convertible warrants will be allocated among five investors, with Mrs. Chigurupati Uma Devi (Promoter) receiving the majority allocation of 2.49 crore warrants, resulting in a post-issue holding of 12.51%. The fundraising proceeds will be utilized for funding business operations, vendor payments, and general corporate purposes.

Regulatory Compliance and Approvals

The fundraising initiative is subject to regulatory approvals and shareholder consent. The relevant date for the preferential issue under SEBI ICDR Regulations is December 23, 2025. The company has appointed a monitoring agency to oversee the utilization of proceeds exceeding ₹100 crores as per regulatory requirements.

Shareholders can access the complete EGM notice and related documents on the company's website at granulesindia.com. The initiative represents a strategic capital raising approach combining multiple instruments to strengthen the pharmaceutical company's financial position for organic and inorganic growth opportunities.

Granules India Limited has announced that its wholly-owned subsidiary, Granules Life Sciences Private Limited (GLS), has successfully concluded a Good Manufacturing Practices (GMP) and Prior Approval Inspection by the U.S. Food and Drug Administration (FDA). The inspection resulted in five procedural observations, with no concerns raised regarding data integrity or product safety standards.

Inspection Timeline and Scope

The FDA inspection was conducted from December 15 to 19, 2025, at the Granules Life Sciences facility located in Hyderabad (FEI: 3030495702). The inspection focused on the facility engaged in manufacturing PFI Finished Dosages, representing a comprehensive evaluation of the company's pharmaceutical manufacturing operations.

Inspection Outcome

The inspection concluded with five observations related to procedural requirements. None of these observations are associated with data integrity or product safety issues, which are among the most critical areas evaluated during pharmaceutical inspections.

Company Response and Commitment

Granules India has committed to addressing the observations promptly and will submit its response to the US FDA within the stipulated timeframe. This approach demonstrates the company's dedication to maintaining regulatory compliance and addressing any procedural improvements identified during the inspection.

Regulatory Significance

The completion of the FDA inspection with only procedural observations reflects positively on Granules Life Sciences' manufacturing standards and quality control processes. The absence of data integrity or product safety issues is particularly significant, as these areas represent core regulatory requirements that directly impact product quality and patient safety in pharmaceutical manufacturing operations.